Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAge Labs (BIOA) EBIT (2024 - 2025)

BioAge Labs (BIOA) has disclosed EBIT for 2 consecutive years, with -$28.4 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 12.07% to -$28.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$92.8 million through Dec 2025, down 18.65% year-over-year, with the annual reading at -$92.8 million for FY2025, 18.65% down from the prior year.
  • EBIT hit -$28.4 million in Q4 2025 for BioAge Labs, down from -$23.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$12.8 million in Q1 2024 to a low of -$28.4 million in Q4 2025.